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Abstract: 
 
We conducted a systematic literature review on psychological and behavioral comorbidities 
in patients with inflammatory neuropathies. In Guillain-Barré syndrome (GBS), psychotic 
symptoms are reported during early stages in 30% of patients. Typical associations include 
mechanical ventilation, autonomic dysfunction, inability to communicate, and severe 
weakness. Anxiety and depression are frequent comorbidities. Anxiety may increase post-
hospital admissions and be a predictor of mechanical ventilation. Post-traumatic stress 
disorder may affect up to 20% of ventilated patients. Sleep disturbances are common in early-
stage GBS, affecting up to 50% of patients. In chronic inflammatory demyelinating 
polyradiculoneuropathy, memory and quality of sleep may be impaired. An independent link 
between depression and pre-treatment upper limb disability and ascites was reported in 
POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin) syndrome, with 
an association with early death. Hematological treatment of POEMS appears effective on 
depression. Published literature on psychological/behavioral manifestations in inflammatory 
neuropathies remains scarce, and further research is needed. 
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Introduction. 
 
Inflammatory neuropathies include a broad and heterogeneous spectrum of conditions that 
share in common focal, multifocal, or generalized sensory and/or motor deficits, 
characterized by acute, progressive, or relapsing and remitting courses [1]. Treatment 
strategies depend on the clinical manifestations. Symptomatic therapies are mainly offered to 
control pain and other sensory symptoms, while the aim of immunomodulation is to improve 
or restore motor and/or sensory function [1]. 
Patients with inflammatory neuropathy, irrespective of subtype, can develop neuropsychiatric 
manifestations that result in significant psychosocial difficulties [2]. The incidence, 
characteristics, implications, and consequences of such disturbances are generally not well 
known, routinely assessed, or adequately considered in routine care of patients with 
inflammatory neuropathy. Neuropsychiatric symptoms may also add significant burden to 
health-related quality of life and have a negative impact on its clinical manifestations such as 
pain, sensory function, and motor performance [3]. Furthermore, it is likely that these aspects 
may have significant implications for therapeutic efficacy and its objective assessment. 
We conducted a systematic review of the scientific literature on the neuropsychiatric 
presentations in patients with inflammatory neuropathies, i.e. Guillain-Barré syndrome 
(GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal 
motor neuropathy, and paraproteinaemic neuropathies, including their different subtypes. We 
aimed to critically appraise the use of neuropsychiatric/psychological assessment protocols in 
clinical practice, both in terms of baseline functional evaluations and measurement of 
therapeutic benefit. 
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Methods. 
 
Our search methodology followed the standard guidelines for systematic literature reviews 
outlined in the PRISMA statement [4]. We conducted a Medline search of all English 
language articles published between January 1966 and January 2016 focusing on the 
psychological and behavioral aspects of all forms of inflammatory neuropathy. We used 
Medline with the MeSH search terms “inflammatory neuropathy”, “Guillain-Barré 
syndrome”, “GBS”, “acute inflammatory demyelinating polyneuropathy”, “AIDP”, “acute 
motor axonal neuropathy”, “AMAN”, “acute motor and sensory axonal neuropathy”, 
“AMSAN”, “chronic inflammatory demyelinating polyneuropathy”, “chronic inflammatory 
demyelinating polyradiculoneuropathy” “CIDP”, “multifocal motor neuropathy”, “MMN”, 
“paraproteinemic demyelinating neuropathy” (“PDN”), “POEMS” (“Polyneuropathy, 
Organomegaly, Endocrinopathy, M-Protein, Skin”) syndrome, “CANOMAD” (“Chronic 
Ataxic Neuropathy with Ophthalmoplegia, M-protein and Disialosyl antibodies”) syndrome, 
each combined with “neuropsychiatric”, “psychiatric”, “psychology” and “psychological 
assessment”, “depression”, “anxiety”, “sleep disorders”, and “psychosis”. The review 
specifically focused on ascertainment of psychological state, treatment effects, and disease 
monitoring. Fatigue was excluded, as we did not consider this an intrinsically 
neuropsychiatric manifestation and recent studies have suggested a neuromuscular basis to 
fatigue in GBS [5]. We nonetheless included results of fatigue assessment in studies which 
captured neuropsychiatric features as a primary or secondary focus. Articles were included 
without regard to disease subtype or course, sample size, analytical approach, monitoring 
strategy, assessment battery, or therapeutic procedure. The papers that met these initial 
selection criteria were read in full-text version and analyzed in detail with special reference to 
neuropsychiatric presentations (psychological/behavioral/mental health/sleep disorders), 
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outcomes and conclusions. Reference lists of retrieved articles were searched for any 
additional relevant publications in the field. The findings are described here using a 
descriptive approach.  
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Results. 
 
We identified a total of 20 original articles with data on neuropsychiatric assessments of 
patients diagnosed with inflammatory neuropathy, and 1 review article published in 2007 [6]. 
Of these 20 original articles, 2 reported on the same group of patients in the setting of an 
interventional study. The original articles we reviewed, which are summarized in Table 1, 
showed considerable heterogeneity in focus. A large number of studies reported the presence 
of neuropsychiatric disorders during or after the acute presentation of GBS. In order to aid 
clarity, we have grouped the studies based on their main focus. 
  
Anxiety, depression, stress and psychotic symptoms.  
 
A prospective study was published in 1983 by Eisendrath et al. on 8 GBS patients [7]. No 
formal psychological testing was used, and evaluations were subjective and unblinded. All 
patients reported moderate to severe anxiety and fear intermittently during their stay in the 
Intensive Care Unit (ICU). Fear of ventilator dysfunction appeared to be common. Anxiety 
was thought to be improved by staff and family support. Six patients remembered visual 
hallucinations. These were usually described as frightening and were occasionally 
accompanied by disorientation. They were common during the plateau phase and were felt to 
be typical of those reported in ICU patients. Depression was noted in 7 patients during the 
recovery phase and was felt to be possibly linked to realization of slow recovery and long 
convalescence. 
A case report of post-traumatic stress disorder (PTSD) in a 24-year old woman following 
severe GBS was published in 1994 [8]. The authors observed that the PTSD in this patent had 
the same clinical features as when it followed other traumatic events. Symptoms had started 
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more than 3 years after GBS, and the link with the neuropathy was only established after 
several consultations. The patient was considered to possibly have a specific predisposition 
due to previous health-related psychological traumas. 
After an initial report of 10 subjects published in German and therefore not included in this 
review [9], a larger prospective study on 49 GBS patients admitted to ICU was undertaken by 
Weiss et al. (2002) who investigated the presence of psychological disturbances in the acute 
phase of the disease [10]. Anxiety was present in 82% of patients, depression in 67%, brief 
reactive psychosis in 25%, and catatonic psychosis in 14%. Psychosis was found to be 
strongly associated with severe tetraparesis, mechanical ventilation, and multiple cranial 
nerve involvement. Those having all 3 had an 85% likelihood of experiencing psychotic 
symptoms. Interestingly, CSF protein levels correlated with the presence of psychotic 
symptoms. Brain imaging obtained in 7 of 12 psychotic patients did not show abnormalities. 
When interviewed after their hospital stay, patients described loss of communication as the 
most stressful problem. When evaluating the subjective experience of ICU stay, 55% of 
patients felt reassured by the ICU environment, whereas 35% experienced long-lasting 
distress due to their ICU stay. Ninety percent described regular visits from relatives as very 
helpful to cope with the psychological distress induced by their disease. 
In 2005, Cochen et al. published a prospective controlled study of mental status abnormalities 
and their determinants in a large study of 139 French GBS patients and 55 control patients 
admitted to ICU with other conditions [11]. Thirty-one percent of GBS patients experienced 
mental status abnormalities that developed at a median time from onset of 9 days, and lasted 
a median of 8 days, with a maximum duration of 133 days. Of those affected, 60% 
(corresponding nearly to 1 patient in 5 of the whole cohort) had visual hallucinations, mainly 
described as tiny colorful and moving figures. Seventy per cent had delusions, mostly of 
paranoid type, whereas illusions were present in 30% of GBS patients who were aware of 
8 
 
visual, tactile, or auditory manifestations. A further 19% experienced vivid, emotional, and 
colorful dreams, with accurate recollection on awakening that often persisted months later. 
Mental status abnormalities were consistently associated with autonomic dysfunction, disease 
severity, need for mechanical ventilation, CSF protein levels, and CSF hypocretin-I levels. 
Moreover, independent associations with mechanical ventilation and CSF protein levels were 
identified. These findings led the authors to conclude that the mental status abnormalities 
experienced by GBS patients are different from ICU delirium and that their most relevant 
associated features were the presence of autonomic dysfunction, severe GBS, and possibly a 
transitory hypocretin-1 transmission decrease.  
In a randomized controlled crossover trial of amantadine versus placebo for fatigue in GBS 
[12], Garssen et al. reported no difference in Fatigue Severity Scale (FSS) changes in 
severely fatigued GBS patients. With relevance to the current review, Hospital Anxiety and 
Depression Scale (HADS) scores were used as secondary outcome measure, and there were 
no significant changes in the 2 treatment arms. However, individual scores were not 
provided, and therefore no useful baseline data were available. 
In a prospective study of the effects of physiotherapist-prescribed community-based exercise 
on 10 GBS patients at least 1 year post-diagnosis and 4 patients with stable CIDP, Graham et 
al. used the HADS and FSS as secondary outcome measures, [13].  The primary outcome 
measure, the Overall Disability Sum Score (ODSS) improved post-treatment by 1 point from 
a baseline level of 3 (P=0.023) and by a further point at 6 months (P=0.008). The HADS 
Anxiety score improved from a median of 6 (compared to 4 in normal controls) by 2 points 
(P=0.02) and by a further 2 points at 6 months (P=0.04). The HADS Depression score 
improved from a median of 1.5 (compared to 1 in normal controls) by a median of 1 point 
(P=0.04) and by a further median of 0.5 points at 6 months (P=0.08). It was not specified 
whether baseline differences in HADS scores were significant between patients and controls. 
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FSS improved from a median of 4.6 points at baseline (significantly higher than in controls, 
median: 3.4) by a median of 0.6 points post-exercise (P=0.009) and by a further median of 
0.6 points at 6 months (P=0.006). 
Bussmann et al. reported the results of a study on the effects of physical exercise in 16 
patients with previous GBS and 4 patients with stable CIDP [14]. Both the FSS and HADS 
were used, as well as the health-related Quality of Life Short Form-36 Questionnaire (SF-36) 
and the Rotterdam Handicap Scale. Measurements were obtained at baseline and after a 
targeted intervention consisting of 3 supervised cycle training sessions on a weekly basis for 
a total of 12 weeks. Mean HADS scores were within normal range at baseline (mean score: 
3.5), however they improved after the physical exercise intervention (mean score: 3.0). 
Changes in HADS score showed a strong correlation with changes in muscle power and 
percentage of active time per 24 hours, as well as the physical component of the Fatigue 
Impact Scale (FIS). On the other hand, baseline FIS ratings revealed a marked increase in 
fatigue symptom severity compared to healthy controls [6.1 versus 2.3 (S.D. 0.7)]. The active 
intervention resulted in a considerable improvement to a mean value of 5.4. Changes in the 
FIS scores also correlated with changes in percentage of active time.  
One case of insomnia, general fatigue, anxiety, and depression in the setting of fulminant 
GBS after Hemophilus influenzae infection was described by Tagami et al. with electrically 
non-excitable nerves and anti-GM1 and GD1a antibodies [15]. Depression persisted despite 
selective serotonin reuptake inhibitor treatment and required long-term psychological 
support. 
Khan et al. investigated factors affecting long-term health-related outcomes in 76 subjects 
who had presented with GBS [16]. According to the Perceived Impact of Problem Profile 
(PIPP), both mood and satisfaction with life were substantially affected in 22%. Anxiety 
(22.4%), depression (18.4%), and stress (17.1%), were reported with higher prevalence than 
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in a control group of healthy individuals. Specifically, women had significantly higher levels 
of anxiety, depression, and stress than men, as measured by both Depression and Anxiety 
Stress Scale 21 (DASS-21) and PIPP. Unsurprisingly, older patients reported higher PIPP 
scores on both self-care and relationships domains, although these ratings did not correlate 
with anxiety, depression, or stress. Interestingly, time since GBS diagnosis (<6 years or >6 
years) had no significant effect on mood. From the point of view of clinical severity 
indicators, ICU admission, length of stay, MRC scores, or discharge destination did not 
predict subsequent development of affective symptoms. Based on their findings, the authors 
concluded that GBS requires long-term management of psychological sequelae affecting 
levels of activity and participation. 
In a subsequent randomized controlled trial of high and low-intensity rehabilitation for late 
stage GBS [17], the same group did not find any difference in psychological outcome 
measures as evaluated by the DASS-21, although they supported a modest benefit for 
reduction in motor disability. Interestingly, using the Perceived Impact of Problem Profile 
(PIPP) scale, significant improvement within the relationship domain was observed following 
intervention (not included in Table 1).  
Bernsen et al. studied 85 Dutch subjects participating in an international double-blind RCT 
comparing intravenous immunoglobulin and placebo, for presence and course of 
psychological distress, depressive symptoms, and health status at 3, 6, and 12 months after 
onset [18]. They used the 28-item version of the General Health Questionnaire (GHQ-28) and 
the Center for Epidemiologic Studies Depression Scale (CES-D) to assess current mental 
state and measure of psychological distress and depressive symptoms. Health status was 
assessed by the Sickness Impact Profile consisting of physical and psychosocial dimensions. 
They found that although psychological distress and depressive symptoms were present and 
more severe/frequent than in the general population in early stages, they improved from 3 to 
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6 months and normalized at 6 months. However, although also showing gradual 
improvement, the psychosocial health status was still impaired at 12 months. Anxiety scores 
remained surprisingly normal throughout the year of study, which was possibly related to the 
delayed first assessment at month 3 or use of anxiolytic therapy. 
Davidson et al. [19] collected outcome data on general mobility, FSS, HADS, and SF-36 in a 
U.K. postal survey of GBS patients. Of the 1,535 patients contacted, 884 questionnaires 
(57.6%) were returned. Mean FSS scores were significantly higher in subjects with minor 
symptoms who were able to run (101 subjects) compared to healthy controls (median scores 
of 4.8 versus 3.2; P<0.001). The group with minor symptoms had higher anxiety levels 
(median of 6 vs. 4; P=0.012) and depression (median of 4 versus 1.5; P<0.001) than healthy 
controls. All domains of the SF-36, including the mental domain, were significantly more 
affected in the minor symptom group compared to healthy controls. These patients did not 
appear to have differences in anxiety and depression ratings in relation to receiving 
physiotherapy treatment at discharge, as it was shown in a separate study by the same authors 
[20] (not included in Table 1.). 
Anxiety at ICU admission for GBS was the focus of a study by Sharshar et al. [21]. In this 
prospective single-center analysis, 110 patients were assessed for intensity and clinical 
features of anxiety on admission using the State Trait Anxiety Inventory Y1 (STAI-Y1) and 
the dyspnea visual analogue score (VAS), to investigate whether anxiety was predictive of 
subsequent respiratory failure. STAI-Y1 scores were above 60/80 in 23 patients (21%), and 
the dyspnea VAS was above 7/10 in 28 patients (26%); the 2 measures were also 
significantly correlated (P<0.0001). Arm disability grade, female gender, disability grade, 
and presence of bulbar dysfunction correlated with STAI-Y1 ratings. Moreover, STAI-Y1 
scores were significantly higher in patients who subsequently required mechanical 
ventilation; these patients considered the uncertainty to be most stressful, whereas patients 
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who did not require mechanical ventilation more often reported pain or weakness as greatest 
stress-generators. Interestingly, feelings of uncertainty (rather than severity of anxiety) were 
most strongly associated with respiratory failure.  
The long-term (defined as ≥12 months) outcome of GBS patients who required mechanical 
ventilation was further investigated by Witsch et al. [22]. Approximately 65% of survivors 
had pain at the time of interview, and nearly 50% had anxiety and depression. Over 30% had 
significant fatigue, with a FSS score above 5.5. Neither anxiety/depression nor fatigue was 
significantly associated with age. There was an unexpected association with treatment type;  
all these neuropsychiatric symptoms had better outcomes after intravenous immunoglobulin 
in comparison to plasma exchange, but the reasons for this are unclear. Administration of 1 
versus multiple immunoglobulin courses had no further impact on subsequent psychological 
state and fatigue severity. 
Karkare et al. studied anxiety and depression as secondary outcome measures using the 
HADS, in their sleep study of 60 GBS patients in the acute phase [23]. They showed that 
23/60 patients (38.3%) had anxiety and 24/60 (40%) had depression. Further details were not 
provided. 
Le Guënnec et al. investigated the impact of prolonged mechanical ventilation by measuring 
the prevalence of PTSD or PTSS (post-traumatic stress symptoms) in GBS patients [24]. The 
Horowitz Impact of Event Scale (IES), the Impact of Event Scale-Revised (IES-R), and the 
Post-traumatic Check List Scale (PCLS) were used to assess PTSD symptoms. Depression 
was assessed using the HADS and Beck Depression Inventory (BDI). Only 13/22 patients 
who had been ventilated for at least 2 months could be included in the study; the mean time 
from weaning from mechanical ventilation to the evaluation was 3 years, with a range 
between 2 and 5 years. Twenty-two per cent of patients fulfilled DSM-IV criteria for PTSD. 
Of note, patients from this small cohort did not report other anxiety or affective symptoms, as 
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measured by psychometric instruments, with median HADS anxiety subscale score of 5 
(range 4–11.5), median HADS depression subscale score of 1 (range 0–3.5), and median BDI 
score of 1 (0–5). 
Ranjani et al. assessed anxiety and depression as correlates of fatigue in GBS in the 
neurorehabilitation setting using the HADS [25]. This study involved 90 subjects and showed 
that, at discharge, fatigue correlated significantly with anxiety (P=0.042) but not with 
depression. The study did not provide detailed data on findings relating to anxiety and 
depression. 
Zhang et al. recently published a large and comprehensive study on the prevalence and 
determinants of depression in patients newly-diagnosed with POEMS syndrome, a relatively 
rare multi-system hematological condition that causes a mixed demyelinating and axonal 
inflammatory neuropathy [26]. In this study, 72 patients were assessed at baseline using the 
Patient Health Questionnaire scale (PHQ-9) and the Overall Neuropathy Limitation Score 
(ONLS). Patients were subsequently re-evaluated at 3-monthly intervals following different 
therapeutic interventions, including autologous stem cell transplant (ASCT), melphalan, and 
dexamethasone. The PHQ-9 is a 9-item self-administered psychometric instrument that 
assesses depressive symptoms. PHQ-9 total scores range between 0 and 27, with higher 
scores indicating more severe depression. Using a cut-off score of 10, the authors of this 
study estimated the prevalence of clinical depression at 38.0% (pre-treatment). Over 70% of 
patients reported at least mild depressive symptoms with a PHQ-9 score above 4, however 
none of them were taking antidepressants. Compared to patients without depression, patients 
with clinical depression had higher ONLS upper limb scores (P=0.03) and lower hemoglobin 
levels (P=0.04), as well as higher rates of physical conditions, including hypothyroidism 
(P=0.01), ascites (P =0.01), and pleural effusion (P=0.03). Interestingly, there was no 
association with serum VEGF (vascular endothelial growth factor) level, a useful disease 
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marker for POEMS. VEGF is a cytokine that has been proposed recently as a marker of 
severe depression, raising the possibility of a link between immunological changes and 
development of affective symptoms in the context of POEMS syndrome [27]. Multivariate 
logistic regression identified only upper limb ONLS scores (P=0.02) and the presence of 
ascites (P=0.04) as independent predictors of clinical depression. The authors commented 
that the association between depression and upper (but not lower) limb ONLS could be due to 
higher impact of arm disability on psychological well-being. Pre-treatment clinical 
depression was otherwise shown to be significantly associated with early death (P=0.04). 
Although no antidepressants were administered, median PHQ-9 scores decreased 
significantly following hematological treatment of the underlying disease (P=0.001). 
Furthermore, incidence of depression dropped from 38% pre-treatment, to <2%, post-
treatment. This led the authors to conclude that antidepressant therapy might not be necessary 
in POEMS patients with pre-treatment depression. Interestingly, although steroids may cause 
depression as a well-known adverse effect, these agents did not appear to have this effect in 
patients with POEMS syndrome who received them as part of their treatment. 
 
Sleep disorders. 
 
Cochen et al. studied both quantitative and qualitative sleep parameters, which they found to 
be poor in all GBS patients; specifically, sleep patterns were fragmented and unstable when 
patients reported mental status abnormalities [10]. In addition, GBS patients and mental 
status abnormalities had major REM (rapid-eye movement) sleep abnormalities, including 
shortened REM sleep latencies, REM sleep without atonia, and abnormal bursts of eye 
movements during non-REM sleep. The authors concluded that the sleep abnormalities in 
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GBS suggested that mental status abnormalities can be difficult to differentiate from wakeful 
dreams caused by underlying sleep disorders. 
Karkare et al. prospectively studied sleep quality in the acute phase of GBS in 60 patients 
using a wide range of assessment tools, including the Pittsburgh Sleep Quality Index (PSQI), 
Richards Campbell Sleep Score, and St. Mary’s Hospital Sleep Questionnaire [22]. Over half 
of the patients had poor sleep during their hospital stay. The authors reported that 22% had 
“poor quality of sleep at baseline” (presumably corresponding to the initial hospital 
assessment rather than to their pre-disease status). Sleep disturbance (defined by a Richards 
Campbell Sleep Score above 33) was significantly associated with anxiety (P=0.009), but not 
with depression, despite a statistical trend that failed to reach significance (P=0.07).  
In a study of CIDP patients by dos Santos et al. [28], daytime sleepiness was reported by a 
third of the recruited sample, and 1 in 6 reported sleeping only 2-4 hours a night, suggesting a 
possible impact of their condition on sleep. The main limitation of this study is that the 
disruption of sleep patterns could only been inferred from self-reported data, as 
polysomnography was not available for objective sleep assessment.   
A study by Ranjani et al. also used the PSQI and reported a 73% rate of sleep disturbance at 
admission, possibly due to a high prevalence of neuropathic pain (77%) and paresthesia 
(60%). There was, however no association with fatigue [25]. 
 
Cognitive dysfunction. 
We found only 1 study of higher cognitive functions in inflammatory neuropathy; it used the 
mini-mental state examination (MMSE) [28]. Forty-one patients with CIDP were studied, and 
the mean MMSE score was 26 (range 22-30). Although cognitive screening did not suggest 
significant impairment , one-third of patients reported memory deficits.  
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Discussion. 
 
We have reviewed the evidence on neuropsychiatric comorbidities in patients with 
inflammatory neuropathies. The first relevant finding was the relative paucity of published 
literature on this topic, which precluded the possibility of complementing this descriptive 
review with secondary data analysis. Furthermore, the variability in assessment methods, 
including psychometric scales, absence of normative values, heterogeneity of study focus, 
and lack of longitudinal data, all represent major limitations in drawing strong conclusions 
from the available evidence.  
 
Most of the available data comes from studies conducted on GBS patients. However, as 
shown by this review, the variability in timing between the acute manifestation and 
psychometric assessment is a strong limitation.  Available data from the studies by Weiss et 
al., Sharshar et al., and Karkare et al. [9, 20, 22] suggest that anxiety is not an uncommon 
finding in the context of acute GBS, with a prevalence ranging from 20% at admission to 
40%-80% during ICU stay. Specifically, early manifestations of anxiety appear to be 
associated with bulbar dysfunction and may interestingly predict the need for subsequent 
mechanical ventilation. Anxiety comorbidity in the longer term is reported with a higher 
frequency compared with the normal population, affecting over 20% of patients with 
previous GBS, as shown by Khan et al. [15]. Similarly, depression and stress appear to be 
more frequent in patients with a history of GBS, even years after the acute episode [15, 20]. 
There is some uncertainty about the duration of psychological distress in view of the findings 
of Bernsen et al. [17]. Both anxiety and depression may correlate with the presence 
neurological disability and persistence of minor symptoms affecting patient wellbeing, even 
in the presence of complete recovery from GBS [18], although there has been no consistency 
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of findings in this regard [17].  Fatigue severity, as well as the mental component of the SF-
36 and pain symptoms appeared to be closely associated with degree of functional recovery. 
Although exclusively a disease of the peripheral nervous system in its classical form, GBS 
appears to be accompanied by early changes in mental status, including hallucinations and 
delusions, in as many as one-third of patients, especially in association with severe weakness, 
mechanical ventilation, and autonomic dysfunction [6, 7]. Whether this may have a central 
mechanism may be possible as suggested by the correlation with CSF protein levels found in 
2 studies [9, 10]. Loss of voluntary movement and ability to communicate may be 
contributors to the development of psychotic symptoms.  
 
However, previously reported high rates of “ICU psychosis” or “hyperactive delirium in 
ICU” reaching up to 60-80% in ventilated subjects, could indirectly support its observation in 
GBS patients [29]. Also, 30% of ventilated ICU patients have been documented to have long-
term cognitive difficulties up to 6 years after hospital discharge [30]. This is in keeping with 
findings in GBS samples [10, 13].  The main differential diagnosis is therefore with ICU 
psychosis. The evidence in Cochen’s study showed that mental status abnormalities were 
twice more frequent in GBS than in ICU controls, despite GBS patients being younger and 
less exposed to psychoactive drugs and metabolic disorders [11]. The onset of 
neuropsychiatric symptoms occurred pre-ICU admission in 16% of GBS patients. There were 
no reported risk factors for ICU delirium in these subjects (i.e. aging, metabolic disorders, use 
of psychoactive drugs, and placement in a windowless ICU area/bay). In addition, the GBS 
patients had qualitatively more elaborate dreams, illusions, and hallucinations, with more 
severe and more frequent delusions. All these elements support that the GBS-psychosis and 
ICU-psychosis are qualitatively distinct manifestations. However, the lack of confirmatory 
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studies since that of Cochen et al., does not allow definite identification of a GBS-specific 
psychosis. 
 
In addition, irrespective of ICU admission, the acuteness and severity of the neuropathy in the 
case of GBS may explain the neuropsychiatric features described. Comparable manifestations 
have been reported with other disorders. After stroke, which causes similarly acute, severe 
disability, rates of depression (29-33%) and anxiety (24%) are higher than in the general 
population [31], and not dissimilar to those reported in several studies in GBS [16, 21-23]. Of 
interest however, only low proportions of stroke patients, ranging from 0.4-3.1%, have a 
psychotic disorder, single psychotic symptoms occur in up to 10% and hallucinations in only 
4% [31]. These figures contrast with the much higher rates reported by Cochen et al. in GBS, 
which supports their hypothesis of a GBS-specific psychosis [11].  
 
In practice, appropriate consideration and exclusion of GBS or neuropathy mimics such as 
porphyria [32] and lead intoxication [33] remain essential in presence of neuropsychiatric 
manifestations, which should not be assumed to necessarily be GBS-related. Adequate 
repeated assessments, maintaining communication, and offering targeted treatment for 
anxiety, depression, and psychosis should be considered. Sleep disturbances are also common 
in the acute phase of GBS, possibly affecting up to 50% of patients [22]. Small case series 
suggest both sleep quality and quantity are probably affected, with sleep fragmentation as 
well as REM sleep abnormalities [10]. However, studies that focus on sleep problems have 
been equally been conducted on very small patient samples, thus limiting generalizability of 
the conclusions [22]. 
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A study on a large cohort of patients with POEMS syndrome, a rare nosological entity, 
showed high prevalence of pre-treatment depression, with figures approaching 40% [26]. 
Independent association between depression and upper limb disability and ascites was shown 
to be a risk factor for early death. Interestingly, treatment of POEMS syndrome without use 
of antidepressants was highly effective in resolving depression in the vast majority of 
patients. Unfortunately, no studies provide data in patients with more common inflammatory 
neuropathies such as CIDP, except for a single analysis assessing basic cognitive function 
[28]. Our review could not identify any relevant data on patients with other inflammatory 
neuropathies.  
 
In conclusion, neuropsychiatric aspects can be of major importance in patients with 
inflammatory neuropathies; their occurrence has the potential to influence the severity of the 
clinical presentation, its functional impact, and health-related quality of life [3]. This 
contrasts with the paucity of studies in this area. As shown in studies on GBS and POEMS 
syndrome, there are significant associations between neuropsychiatric comorbidities and 
physical ability and, importantly for clinical practice, even subtle physical deficits appear 
related to anxiety and depression. It seems likely that similar features may be present to 
varying degrees in all types of inflammatory neuropathies. The therapeutic implications of 
the POEMS syndrome study are of great interest; in addition to the effects on the neuropathy, 
treatment had additional measurable effects on patients’ mood. In CIDP and multifocal motor 
neuropathy, knowledge of neuropsychiatric symptoms at baseline would be of great interest. 
Their progression with treatment, together with their actual impact on treatment effectiveness 
and ease of monitoring, also deserve investigation. These aspects are likely to be of potential 
relevance to improve the understanding of disease profiles and to implement more effective 
management strategies.  
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Further studies are needed to understand the prevalence and implications of the 
neuropsychiatric aspects of inflammatory neuropathies. This may improve future global care 
and management of patients, taking into account this so-far generally poorly understood and 
neglected aspect of this group of disorders. 
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Table 1. Studies on Neuropsychiatric manifestations in inflammatory neuropathies (Medline search of 
articles 1966-January 2016).  
 
Paper   Neuropathy 
Subtype(s) 
Number 
of  Participants  
Main Findings  
 
Eisendrath et al. [7] GBS 8 Anxiety (100%); Hallucinations (75%) 
Depression  (87.5%) 
Chemtob and Herriott [8] 
 
GBS 1 Post-traumatic stress disorder 
Weiss et al. [9] GBS 49 Anxiety (82%); Depression (67%) 
Brief reactive psychosis (25%); catatonic psychosis (14%) 
Cochen et al. [11] GBS 139 Mental status abnormalities (31%) 
(visual hallucinations, delusions, dreams) 
Garssen et al. [12] GBS 80 Ineffectiveness of amantadine for tiredness 
Graham et al. [13] GBS, CIDP 14 Greater anxiety and depression in patients than in controls (significance unknown) 
Improved anxiety (significant) and depression (non-significant) with exercise 
Bussmann et al. [14] GBS, CIDP 20 Anxiety and depression comparable to controls 
Fatigue severity greater than in controls 
Tagami et al. [15] GBS 1 Severe anxiety and depression in fulminant Guillain-Barré syndrome after Haemophilus influenzae infection 
Khan et al. [16] GBS 76 Higher prevalence of anxiety, depression and stress than in controls 
Bernsen et al. [18] GBS 85 Psychological distress and 
depressive symptoms present but improved between 3-6 months, normalizing at 6 months. 
Davidson et al. [19] GBS 884 Greater fatigue severity and anxiety  in subjects with minor symptoms 
Sharshar et al. [21] GBS 110 Anxiety (21%) Correlation of anxiety with dyspnoea 
Witsch et al. [22] GBS 110 Anxiety and depression in 50% 
Fatigue Severity Score >5.5 in >30% 
Karkare et al. [23] GBS 60 Poor sleep (22%) 
Anxiety and depression (about 40%) 
Ranjani et al. [25] GBS 90 Anxiety but not depression correlates with fatigue 
Le Guënnec et al. [24] GBS 13 Post-traumatic stress disorder (22%) 
 
dos Santos et al. [28] CIDP 
 
41 Mean MMSE of 26/30 
Memory deficits in 1/3 
Day-time sleepiness in 1/3 
Zhang et al. [26] POEMS  
 
72 >70% with at least mild depression at baseline 
Association of depression with upper limb disability and ascites. Improvement with treatment of POEMS 
without antidepressants 
 
Abbreviations: GBS: Guillain-Barré syndrome; CIDP: chronic inflammatory demyelinating polyneuropathy; 
POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein, Skin 
 
 
  
